Natural Cycles, the Swedish startup that became the first mobile application to receive FDA clearance as a contraceptive method, is entering a new phase. After a decade built around a single algorithmic product — one that uses basal body temperature data to predict fertility windows — the company is expanding into perimenopause, a transition that typically begins in a woman's forties and can last several years. The move signals a shift from single-purpose utility to something closer to a longitudinal health platform.

The expansion is not arbitrary. Perimenopause involves the same hormonal fluctuations that Natural Cycles already tracks — shifts in estrogen and progesterone that affect cycle length, ovulation patterns, and body temperature. For a company that has spent a decade refining its temperature-based algorithms, applying that infrastructure to a different life stage represents a logical extension of existing capabilities rather than a leap into unfamiliar territory.

From contraception to platform

The strategic logic mirrors a pattern familiar in health technology: a company earns regulatory credibility and user trust through a narrow, well-defined product, then leverages that foundation to address adjacent needs. Fitbit followed a similar trajectory, moving from step counting to heart-rate monitoring to FDA-cleared electrocardiogram features. The challenge, as those precedents illustrate, is that each new clinical claim invites fresh regulatory scrutiny. Medical-grade software operates under a different burden of proof than consumer wellness apps, and Natural Cycles has historically positioned itself on the medical side of that divide.

The perimenopause market itself is drawing increased attention across the broader femtech sector — a category that encompasses digital health products designed around female physiology. For years, femtech attracted modest venture capital relative to its addressable population. That dynamic has shifted. Investors have recognized that women's health extends well beyond fertility and pregnancy, and companies addressing menopause-related needs are beginning to attract more substantial funding rounds. Natural Cycles, with its established regulatory track record and a user base that is itself aging into perimenopause, holds a structural advantage in this expanding market.

The investor question

The company's maturation is not only clinical but financial. Having raised nearly $100 million over its lifetime, Natural Cycles now faces a challenge common to venture-backed firms that survive past the ten-year mark: early investors need liquidity. CEO and co-founder Elina Berglund has indicated that a reshuffling of the investor base may be approaching, with a secondary sale of shares as a likely mechanism. Secondary transactions allow early backers to realize returns without requiring the company itself to pursue an IPO or acquisition — events that carry their own strategic costs and timing constraints.

This dynamic is increasingly visible across the European startup ecosystem, where companies that raised capital during the low-interest-rate era of the mid-2010s are now under pressure to provide exits. The tension between building a durable, regulation-heavy health business and satisfying venture capital's return timelines is not unique to Natural Cycles, but it is particularly acute in medtech, where product cycles and regulatory approvals move slower than investor patience typically allows.

Berglund continues to lead the company remotely, from a distance reported at roughly 6,000 kilometers from the main office. The remote-first model raises questions that extend beyond operational efficiency. In the post-Dobbs regulatory environment in the United States — where reproductive health data has become a subject of legal and political scrutiny — data governance is not merely a technical concern but a reputational and legal one. How a health platform handles sensitive fertility and hormonal data, and under which jurisdiction that data is stored and processed, carries weight that it did not carry five years ago.

Natural Cycles now sits at the intersection of several forces: a femtech sector gaining institutional legitimacy, a user base whose needs are evolving beyond contraception, investors seeking overdue returns, and a regulatory landscape that is simultaneously more receptive to digital health tools and more vigilant about the data they collect. Whether the company can navigate all four pressures simultaneously — expanding its clinical scope while restructuring its cap table and maintaining data trust — will determine whether it becomes a lasting institution in digital health or a case study in the limits of venture-backed medtech.

With reporting from Breakit.

Source · Breakit